<DOC>
	<DOCNO>NCT02099370</DOCNO>
	<brief_summary>The investigator measure adherence rate oral MS drug administer twice-daily . The investigator would like observe pattern might indicate factor greatly affect adherence .</brief_summary>
	<brief_title>Adherence Treatment With Tecfideraâ„¢ Multiple Sclerosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Must give write informed consent authorization require local law ( e.g. , Protected Health Information [ PHI ] ) . Aged 18 time inform consent . Must relapse form MS . Male subject female subject childbearing potential ( include female subject postmenopausal least 1 year ) must willing practice effective contraception ( defined investigator ) study willing able continue contraception 30 day last dose study treatment . Progressive form MS History severe allergic anaphylactic reaction know drug hypersensitivity . Female subject consider become pregnant study . Female subject currently pregnant breastfeeding . Unwillingness inability comply requirement protocol include presence conditional ( physical , mental social ) likely affect subject 's ability comply protocol . Any reason , opinion Investigator and/or Sponsor , subject determine unsuitable enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Tecfidera ( R )</keyword>
	<keyword>Oral medication</keyword>
	<keyword>Adherence</keyword>
</DOC>